Dermata Therapeutics, Inc. SEC filings DRMA
Dermata Therapeutics, Inc. has 371 filings in SEC EDGAR's recent list, going back to Apr 2, 2021. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 424B3 | Prospectus | Oct 21, 2026 | — |
| EFFECT | Filing | Oct 20, 2026 | — |
| S-3 | Shelf registration | Oct 9, 2026 | — |
| 25-NSE | Delisting notice | Aug 17, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 17, 2026 | Aug 16, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Other events
|
Aug 5, 2026 | Aug 5, 2026 |
| S-8 | Employee stock plan registration | Jun 4, 2026 | — |
| EFFECT | Filing | May 29, 2026 | — |
| 424B3 | Prospectus | May 29, 2026 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 27, 2026 | May 27, 2026 |
| CORRESP | Letter to the SEC | May 27, 2026 | — |
| S-3/A | Filing | May 22, 2026 | — |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 17, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 17, 2026 | — |
| DEF 14A | Proxy statement | Apr 17, 2026 | Apr 17, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 7, 2026 | Apr 6, 2026 |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 26, 2026 | Mar 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 25, 2026 | Feb 23, 2026 |
| 8-K |
Current report
Auditor change
|
Feb 3, 2026 | Jan 30, 2026 |
| EFFECT | Filing | Jan 29, 2026 | — |
| 424B3 | Prospectus | Jan 29, 2026 | — |
| CORRESP | Letter to the SEC | Jan 27, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 27, 2026 | — |
| 8-K |
Current report
Other events
|
Jan 27, 2026 | Jan 27, 2026 |
| 424B5 | Prospectus supplement | Jan 27, 2026 | — |
| S-3 | Shelf registration | Jan 22, 2026 | — |
| D | Filing | Jan 7, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Dec 29, 2025 | Dec 23, 2025 |
| S-3 | Shelf registration | Nov 24, 2025 | — |
| 8-K |
Current report
Agreement ended
|
Nov 18, 2025 | Nov 17, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 14, 2025 | Nov 14, 2025 |
| 8-K |
Current report
Other events
|
Nov 7, 2025 | Nov 7, 2025 |
| 424B5 | Prospectus supplement | Nov 7, 2025 | — |
| 8-K |
Current report
Other events
|
Sep 17, 2025 | Sep 17, 2025 |
| 8-K |
Current report
Other events
|
Sep 10, 2025 | Sep 10, 2025 |
| 8-K |
Current report
Other events
|
Aug 25, 2025 | Aug 22, 2025 |
| 10-Q | Quarterly report | Aug 13, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2025 | Aug 13, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jul 30, 2025 | Jul 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jul 16, 2025 | Jul 15, 2025 |
| 8-K |
Current report
Listing notice
|
Jul 7, 2025 | Jul 2, 2025 |
| 8-K |
Current report
Auditor change
|
Jun 5, 2025 | Jun 3, 2025 |
| ARS | Annual report to shareholders | Jun 2, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Jun 2, 2025 | — |
| DEF 14A | Proxy statement | Jun 2, 2025 | Jun 2, 2025 |
| PRE 14A | Preliminary proxy statement | May 23, 2025 | May 23, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 21, 2025 | May 20, 2025 |
| 8-K |
Current report
Listing notice
|
May 16, 2025 | May 14, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 14, 2025 | May 14, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| EFFECT | Filing | Apr 23, 2025 | — |
| 424B3 | Prospectus | Apr 23, 2025 | — |
| CORRESP | Letter to the SEC | Apr 21, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 21, 2025 | — |
| S-3 | Shelf registration | Apr 15, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 15, 2025 | Apr 15, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights
|
Mar 28, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 27, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Listing notice
|
Mar 25, 2025 | Mar 25, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 17, 2025 | Mar 17, 2025 |
| 10-K | Annual report | Mar 17, 2025 | Dec 31, 2024 |
| EFFECT | Filing | Feb 5, 2025 | — |
| 424B3 | Prospectus | Feb 5, 2025 | — |
| D/A | Filing | Feb 4, 2025 | — |
| CORRESP | Letter to the SEC | Feb 3, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2025 | — |
| S-3 | Shelf registration | Jan 30, 2025 | — |
| D | Filing | Jan 28, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jan 23, 2025 | Jan 21, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jan 21, 2025 | Jan 17, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 14, 2024 | Nov 13, 2024 |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| D | Filing | Sep 27, 2024 | — |
| EFFECT | Filing | Sep 24, 2024 | — |
| 424B3 | Prospectus | Sep 24, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2024 | — |
| CORRESP | Letter to the SEC | Sep 23, 2024 | — |
| S-3 | Shelf registration | Sep 19, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Sep 17, 2024 | Sep 16, 2024 |
| S-8 | Employee stock plan registration | Aug 7, 2024 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 7, 2024 | Aug 7, 2024 |
| 10-Q | Quarterly report | Aug 7, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Other events
|
Aug 2, 2024 | Aug 2, 2024 |
| 424B5 | Prospectus supplement | Aug 2, 2024 | — |
| 424B3 | Prospectus | Jul 15, 2024 | — |
| EFFECT | Filing | Jul 12, 2024 | — |
| CORRESP | Letter to the SEC | Jul 10, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2024 | — |
| S-3 | Shelf registration | Jul 3, 2024 | — |
| 8-K |
Current report
Material agreement
|
Jun 7, 2024 | Jun 7, 2024 |
| 424B5 | Prospectus supplement | Jun 7, 2024 | — |
| 8-K |
Current report
Other events
|
Jun 5, 2024 | Jun 4, 2024 |
| 8-K |
Current report
Listing notice
|
May 24, 2024 | May 20, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights
|
May 17, 2024 | May 17, 2024 |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 15, 2024 | May 15, 2024 |
| 8-K |
Current report
Listing notice, Other events
|
May 15, 2024 | May 14, 2024 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
May 14, 2024 | May 14, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 7, 2024 | May 7, 2024 |
| ARS | Annual report to shareholders | Mar 26, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Mar 26, 2024 | — |
| DEF 14A | Proxy statement | Mar 26, 2024 | Mar 5, 2024 |
| 10-K | Annual report | Mar 21, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 21, 2024 | Mar 21, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 4, 2024 | Feb 28, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jan 12, 2024 | Jan 12, 2024 |
| EFFECT | Filing | Dec 15, 2023 | — |
| 424B3 | Prospectus | Dec 15, 2023 | — |
| CORRESP | Letter to the SEC | Dec 13, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 13, 2023 | — |
| DEF 14A | Proxy statement | Dec 8, 2023 | Dec 7, 2023 |
| S-3 | Shelf registration | Dec 7, 2023 | — |
| PRE 14A | Preliminary proxy statement | Nov 29, 2023 | Nov 28, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights
|
Nov 17, 2023 | Nov 16, 2023 |
| 8-K |
Current report
Listing notice
|
Nov 16, 2023 | Nov 15, 2023 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations, Auditor change, Regulation FD disclosure
|
Nov 9, 2023 | Nov 9, 2023 |
| S-8 | Employee stock plan registration | Sep 14, 2023 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 10, 2023 | Aug 10, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Auditor change, Officer or director change, Shareholder vote results
|
Aug 3, 2023 | Jul 28, 2023 |
| EFFECT | Filing | Jul 27, 2023 | — |
| 424B4 | Prospectus | Jul 27, 2023 | — |
| CORRESP | Letter to the SEC | Jul 25, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 14, 2023 | — |
| DEFA14A | Additional proxy material | Jul 12, 2023 | — |
| S-1 | Registration statement | Jul 7, 2023 | — |
| ARS | Annual report to shareholders | Jun 23, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Jun 23, 2023 | — |
| DEF 14A | Proxy statement | Jun 23, 2023 | Aug 3, 2023 |
| D | Filing | Jun 12, 2023 | — |
| 424B5 | Prospectus supplement | May 25, 2023 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
May 24, 2023 | May 23, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 11, 2023 | May 11, 2023 |
| 10-K/A | Amended annual report | Mar 28, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Other events
|
Mar 28, 2023 | Mar 28, 2023 |
| 424B3 | Prospectus | Mar 21, 2023 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Mar 20, 2023 | Mar 16, 2023 |
| 424B4 | Prospectus | Mar 20, 2023 | — |
| EFFECT | Filing | Mar 16, 2023 | — |
| CORRESP | Letter to the SEC | Mar 16, 2023 | — |
| CORRESP | Letter to the SEC | Mar 16, 2023 | — |
| S-1/A | Amended registration statement | Mar 16, 2023 | — |
| S-1/A | Amended registration statement | Mar 15, 2023 | — |
| CORRESP | Letter to the SEC | Mar 14, 2023 | — |
| CORRESP | Letter to the SEC | Mar 14, 2023 | — |
| S-1/A | Amended registration statement | Mar 13, 2023 | — |
| CORRESP | Letter to the SEC | Mar 13, 2023 | — |
| CORRESP | Letter to the SEC | Mar 13, 2023 | — |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Mar 13, 2023 | Mar 13, 2023 |
| UPLOAD | Letter from the SEC | Mar 6, 2023 | — |
| S-1 | Registration statement | Mar 1, 2023 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Feb 21, 2023 | Feb 21, 2023 |
| 10-K | Annual report | Feb 21, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Feb 8, 2023 | Feb 8, 2023 |
| DEF 14A | Proxy statement | Jan 13, 2023 | Jan 11, 2023 |
| PRE 14A | Preliminary proxy statement | Jan 3, 2023 | Jan 3, 2023 |
| RW | Filing | Dec 29, 2022 | — |
| 8-K |
Current report
Listing notice, Other events
|
Dec 15, 2022 | Dec 15, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 5, 2022 | Dec 5, 2022 |
| EFFECT | Filing | Nov 25, 2022 | — |
| CORRESP | Letter to the SEC | Nov 22, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2022 | — |
| S-3 | Shelf registration | Nov 15, 2022 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 10, 2022 | Nov 10, 2022 |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 23, 2022 | Sep 21, 2022 |
| S-8 | Employee stock plan registration | Aug 26, 2022 | — |
| 10-Q | Quarterly report | Aug 15, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 15, 2022 | Aug 15, 2022 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jul 11, 2022 | Jul 11, 2022 |
| 424B3 | Prospectus | Jun 24, 2022 | — |
| 8-K |
Current report
Officer or director change
|
Jun 24, 2022 | Jun 21, 2022 |
| 8-K |
Current report
Listing notice
|
Jun 22, 2022 | Jun 17, 2022 |
| DEFA14A | Additional proxy material | Jun 1, 2022 | — |
| DEF 14A | Proxy statement | Jun 1, 2022 | Jul 11, 2022 |
| PRE 14A | Preliminary proxy statement | May 20, 2022 | May 20, 2022 |
| 424B3 | Prospectus | May 19, 2022 | — |
| 8-K |
Current report
Other events
|
May 17, 2022 | May 17, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 16, 2022 | May 16, 2022 |
| 10-Q | Quarterly report | May 16, 2022 | Mar 31, 2022 |
| EFFECT | Filing | May 13, 2022 | — |
| 424B4 | Prospectus | May 13, 2022 | — |
| CORRESP | Letter to the SEC | May 11, 2022 | — |
| UPLOAD | Letter from the SEC | May 10, 2022 | — |
| S-1 | Registration statement | May 4, 2022 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Apr 25, 2022 | Apr 20, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 28, 2022 | Mar 28, 2022 |
| 10-K | Annual report | Mar 28, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Other events
|
Mar 2, 2022 | Mar 2, 2022 |
| S-1/A | Amended registration statement | Feb 7, 2022 | — |
| FWP | Free writing prospectus | Feb 4, 2022 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DRMA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1853816
- Former names
- Dermata Therapeutics, Inc. (until Nov 2, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.